India News: Serum Institute of India's CEO Adar Poonawalla will get 'Y' category security across India by the CRPF, the Union government officials said on Wednesd
According to officials, the protection has been given in view of potential threats to Poonawalla.
Share Via Email
| A+A A- By PTI
NEW DELHI: Serum Institute of India s CEO Adar Poonawalla has been accorded Y category security across India by the CRPF in view of potential threats to the businessman, involved in the production of one of the COVID-19 vaccines in India, the Union government officials said on Wednesday.
The Central government decision came after Director, Government and Regulatory Affairs at Pune-based Serum Institute of India (SII), Prakash Kumar Singh had written to Union Home Minister Amit Shah on April 16 requesting security for Poonawalla.
: Wednesday, April 28, 2021, 5:56 PM IST
Serum Institute reduces price of its COVID-19 vaccine Covishield to Rs 300 per dose to states: CEO Adar Poonawalla
Serum Institute reduces price of its COVID-19 vaccine Covishield to Rs 300 per dose to states: CEO Adar Poonawalla
The Serum Institute of India (SII) has reduced the price of its COVID-19 vaccine Covishield from Rs. 400 to Rs. 300 per dose to the states, said CEO Adar Poonawalla on Wednesday. As a philanthropic gesture on behalf of @SerumInstIndia, I hereby reduce the price to the states from Rs.400 to Rs.300 per dose, effective immediately; this will save thousands of crores of state funds going forward. This will enable more vaccinations and save countless lives, Poonawalla tweeted.
Malaria vaccine shows high efficacy
doi:10.1038/nindia.2021.60 Published online 28 April 2021
A malaria
vaccine, administered to African children living in a malaria-endemic region,
has proven to be up to 77 per cent effective
1.
The research,
published preprint (yet to be peer reviewed) meets the 75 per cent efficacy
goal set by the World Health Organization.
A one-year follow-up study has shown that the vaccine is well-tolerated
with mild or no adverse side effects among the children, according to an
international research team. The researchers say that it is possible to
mass-produce the vaccine at an affordable cost to better control, and
eventually eradicate, malaria.